Literature DB >> 22349504

Label-free impedance responses of endogenous and synthetic chemokine receptor CXCR3 agonists correlate with Gi-protein pathway activation.

Anne O Watts1, Danny J Scholten, Laura H Heitman, Henry F Vischer, Rob Leurs.   

Abstract

The chemokine receptor CXCR3 is a G-protein-coupled receptor that signals through the Gα(i) class of heterotrimeric G-proteins. CXCR3 is highly expressed on activated T cells and has been proposed to be a therapeutic target in autoimmune disease. CXCR3 is activated by the chemokines CXCL9, CXCL10 and CXCL11. CXCR3 signaling properties in response to CXCL10, CXCL11 and the synthetic agonist VUF10661 have previously been evaluated using conventional endpoint assays. In the present study, label-free impedance measurements were used to characterize holistic responses of CXCR3-expressing cells to stimulation with chemokines and VUF10661 in real time and to compare these responses with both G-protein and non-G-protein (β-arrestin2) mediated responses. Differences in response kinetics were apparent between the chemokines and VUF10661. Moreover, CXCR3-independent effects could be distinguished from CXCR3-specific responses with the use of the selective CXCR3 antagonist NBI-74330 and the Gα(i) inhibitor pertussis toxin. By comparing the various responses, we observed that CXCL9 is a biased CXCR3 agonist, stimulating solely G-protein-dependent pathways. Moreover, CXCR3-mediated changes in cellular impedance correlated with G-protein signaling, but not β-arrestin2 recruitment.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22349504     DOI: 10.1016/j.bbrc.2012.02.036

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

1.  Biased agonism as a mechanism for differential signaling by chemokine receptors.

Authors:  Sudarshan Rajagopal; Daniel L Bassoni; James J Campbell; Norma P Gerard; Craig Gerard; Tom S Wehrman
Journal:  J Biol Chem       Date:  2013-10-21       Impact factor: 5.157

Review 2.  Pancreatic islet inflammation: an emerging role for chemokines.

Authors:  J Jason Collier; Tim E Sparer; Michael D Karlstad; Susan J Burke
Journal:  J Mol Endocrinol       Date:  2017-04-18       Impact factor: 5.098

3.  Signaling properties of the human chemokine receptors CXCR4 and CXCR7 by cellular electric impedance measurements.

Authors:  Jordi Doijen; Tom Van Loy; Wouter De Haes; Bart Landuyt; Walter Luyten; Liliane Schoofs; Dominique Schols
Journal:  PLoS One       Date:  2017-09-25       Impact factor: 3.240

Review 4.  The Distinct Roles of CXCR3 Variants and Their Ligands in the Tumor Microenvironment.

Authors:  Nathan Reynders; Dayana Abboud; Alessandra Baragli; Muhammad Zaeem Noman; Bernard Rogister; Simone P Niclou; Nikolaus Heveker; Bassam Janji; Julien Hanson; Martyna Szpakowska; Andy Chevigné
Journal:  Cells       Date:  2019-06-18       Impact factor: 6.600

5.  Cellular Electrical Impedance as a Method to Decipher CCR7 Signalling and Biased Agonism.

Authors:  Nathan Vanalken; Katrijn Boon; Jordi Doijen; Dominique Schols; Tom Van Loy
Journal:  Int J Mol Sci       Date:  2022-08-10       Impact factor: 6.208

6.  Co-expression of VAL- and TMT-opsins uncovers ancient photosensory interneurons and motorneurons in the vertebrate brain.

Authors:  Ruth M Fischer; Bruno M Fontinha; Stephan Kirchmaier; Julia Steger; Susanne Bloch; Daigo Inoue; Satchidananda Panda; Simon Rumpel; Kristin Tessmar-Raible
Journal:  PLoS Biol       Date:  2013-06-11       Impact factor: 8.029

7.  Impedance-based analysis of mu opioid receptor signaling and underlying mechanisms.

Authors:  David Thirkettle-Watts
Journal:  Biochem Biophys Rep       Date:  2016-03-03

8.  A label-free impedance assay in endothelial cells differentiates the activation and desensitization properties of clinical S1P1 agonists.

Authors:  Patrick Grailhe; Asma Boutarfa-Madec; Philippe Beauverger; Philip Janiak; Ashfaq A Parkar
Journal:  FEBS Open Bio       Date:  2020-09-04       Impact factor: 2.792

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.